Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. 1991

C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
Department of Gynecology, University of Texas M. D. Anderson Cancer Center, Houston 77030.

Tumor-associated lymphocytes (TAL) were isolated from the ascitic fluid of patients with adenocarcinoma of the ovary. These cells proliferated and expanded by 100-600-fold as either CD3+ CD4+ or CD3+ CD8+ cultures in the presence of moderate concentrations (50-200 cetus units/ml) of recombinant interleukin 2 and reached high numbers (5 x 10(8)-1 x 10(9)). After expansion of 16 TAL samples from 15 patients, 5 of the 7 isolated ovarian cytotoxic T-lymphocyte cell lines of T-cell receptor (TCR) (alpha beta)+ CD3+ CD8+ CD4- phenotype exhibited preferential cytolytic activity against autologous tumor targets and significantly lower cytolytic activity against allogeneic tumor targets and the natural killer-sensitive cell line K562. The cytolytic activity of the CD8+ TAL was inhibited by operationally anti-TCR (alpha beta) monoclonal antibody and monoclonal antibody specific for the CD3 differentiation antigen, indicating that the TCR and CD3 are involved in the cytolytic process. The other TAL cultures demonstrated similar cytolytic activity against both autologous and allogeneic tumors. The phenotype of these TAL was predominantly TCR (alpha beta)+ CD3+ CD4+ CD8-. Certain CD3+ CD8+ T-cell clones isolated from representative TAL exhibited preferential autologous tumor-specific cytotoxicity that may be major histocompatibility complex restricted. Other CD3+ CD8+ and CD3+ CD4+ clones exhibited nonmajor histocompatibility complex restricted cytotoxicity. These results demonstrate that CD3+ CD4+ and CD3+ CD8+ T-cells present in the ovarian malignant ascites can be propagated in large numbers and for long time intervals as T-cell lines in vitro. This finding may be significant for further investigation of ovarian tumor-specific cytotoxic T-lymphocytes and future adoptive specific immunotherapy studies.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
May 1989, Journal of immunology (Baltimore, Md. : 1950),
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
August 1994, Cancer,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
January 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
May 1997, International journal of cancer,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
January 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
January 2015, Asian Pacific journal of cancer prevention : APJCP,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
January 2015, Cancer biology & therapy,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
October 1998, Zhonghua fu chan ke za zhi,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
November 2009, Anticancer research,
C G Ioannides, and C D Platsoucas, and S Rashed, and J T Wharton, and C L Edwards, and R S Freedman
January 1993, Archivum immunologiae et therapiae experimentalis,
Copied contents to your clipboard!